Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash & Equivalents (2018 - 2025)

Exagen (XGN) has disclosed Cash & Equivalents for 8 consecutive years, with $32.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 46.12% year-over-year to $32.2 million, compared with a TTM value of $32.2 million through Dec 2025, up 46.12%, and an annual FY2025 reading of $32.2 million, up 46.12% over the prior year.
  • Cash & Equivalents was $32.2 million for Q4 2025 at Exagen, down from $35.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $118.0 million in Q1 2021 and bottomed at $11.2 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $54.4 million, with a median of $36.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents skyrocketed 76.73% in 2021, then tumbled 58.92% in 2025.
  • Year by year, Cash & Equivalents stood at $99.4 million in 2021, then tumbled by 37.26% to $62.4 million in 2022, then crashed by 41.51% to $36.5 million in 2023, then tumbled by 39.62% to $22.0 million in 2024, then skyrocketed by 46.12% to $32.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for XGN at $32.2 million in Q4 2025, $35.7 million in Q3 2025, and $30.0 million in Q2 2025.